Abcuro: Series DDevelops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseasesOct 4, 2026RoundOSAbcuroCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedBiotechUnited StatesNorth AmericaSeries C+